Europe

People with Alzheimer’s disease who used antiepileptic drugs had a higher number of accumulated hospital days than people with Alzheimer’s disease who did not use antiepileptics, according to a new study from the University of Eastern Finland.
Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.
Hampton has served as chairman of the board since 2015. He decided to part ways with the company as it plans to separate into two entities.
OCR and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies that allows drug efficacy and target exposure services at cellular level using Pets with naturally occurring tumors.
Novartis and Oxford will use artificial intelligence and advanced analytics to identify early predictors of inflammatory diseases.
FDA
Yesterday, the Endocrinologic and Metabolic Drugs Advisory Committee had a split vote, 8 to 8, on whether the overall benefits of Zynquista (sotagliflozin) outweiged the risk in order to support approval. This sends things back to the agency to make a final decision, which has a target action date of March 22, 2019.
MorphoSys AG announced that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC).
Pharnext SA announced the publication of new preclinical results for its lead PLEODRUG(TM) PXT3003 in PLOS ONE showing that early treatment with PXT3003 in a transgenic rat model delays the onset of Charcot-Marie-Tooth disease Type 1A (CMT1A).
A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors.
Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids
PRESS RELEASES